- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03680664
Mindfulness-Based Stress Reduction (MBSR) and Transcranial Direct Current Stimulation (tDCS)
Enhancing Cognition in Older Persons: A Randomized Controlled Trial of Mindfulness-Based Stress Reduction (MBSR) and Transcranial Direct Current Stimulation (tDCS)
Ideal interventions for the older aged population would be those that are easily accessible and associated with minimal burden on family members, the healthcare system and the individuals themselves. Mindfulness-Based Stress Reduction (MBSR) therapy and Transcranial Direct Current Stimulation (tDCS) are two interventions that may be effective in targeting cognitive deficits in individuals with anxiety, depression, and/or cognitive complaints. MBSR has been shown to decrease symptoms of depression and improve cognition and tDCS has been shown to improve cognition in the older aged population. The effectiveness of these two interventions combined to elicit changes in cognition has yet to be demonstrated. Therefore, the overall aim of the current research is to evaluate the efficacy of a combination of MBSR and tDCS to improve cognitive function in individuals with cognitive complaints and symptoms of anxiety and/or depression.
This will be a randomized pilot study. Sixteen individuals (separated into 2 groups of 8) will be randomized to receive a combination MBSR + active tDCS or MBSR + sham tDCS over 8 weeks. Participants will visit the Centre for Addiction and Mental Health (CAMH) once per week for in-class group sessions and will complete the intervention daily at home for the duration of the study. Participants will be aged 60 and older with cognitive complaints, with symptoms of anxiety and/or depression. Participants will be trained to self-administer tDCS and given guidelines for the completion of daily MBSR activities at home. It is hypothesized that the combination of active tDCS + MBSR will enhance cognition compared to the combination of sham tDCS + MBSR.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Neurocognitive difficulties are a common problem in the older adult population. Previous research has shown memory complaints are higher in older adults with depression or anxiety versus those without these diagnoses. This suggests that mood symptoms, or a diagnosis of a mood disorder, may represent significant predictors of cognitive impairment. If left untreated, symptoms of depression and memory complaints may lead to greater cognitive impairment i.e. Mild Cognitive Impairment (MCI) and diagnosis of dementia . Therefore, early interventions are urgently needed to prevent decline in memory and cognitive function in individuals with MCI, depression, and/or anxiety.
This will be a randomized study design. Uo to 24 individuals (n=8 per group) will be randomized to receive a combination of 8-weeks of in-class group MBSR + active or sham tDCS and daily at-home MBSR + tDCS (active or sham). Each individual must be: (1) 60 or above; (2) present with cognitive complaints but not frank cognitive impairment (at a level of mild dementia or greater); and (3) present with a diagnosis or symptoms of depressed mood and/or anxiety.
Symptoms related to cognition, memory, and mood symptoms will be assessed at baseline (T0), throughout the study, as described in the MBSR protocol, and upon completion of the 8-week treatment course (Tx). Each study participant will have a clinical assessment at both T0 and Tx. Clinicians, participants and assessors will be blinded to the tDCS condition. These assessments will confirm any diagnoses and monitor clinical stability, including possible progression of participants to a diagnosis of a mood and/or anxiety disorder(s) or dementia. Any participant that progresses into a clinical diagnosis of dementia will be excluded from the study and referred to an appropriate level of care based on the severity of their symptoms.
To train participants on the tDCS intervention, each individual will attend one-week of in-class training sessions prior to initiating the 8-week study. Participants will come to the Centre for Addiction and Mental Health (CAMH) for 5 days leading up to the initiation of the MBSR treatment for tDCS self-administration training. On the final day of tDCS training, participants will attend a 2.5 hour in-class MBSR orientation session. Following this, the 8-week course of daily MBSR + tDCS will begin with an initial orientation session. The remaining 8 weeks of the at-home MBSR + tDCS intervention will be self-conducted at each participant's place of residence, with the exception of the weekly MBSR class each participant will be required to attend at CAMH. The study coordinator will be available by phone to the participants throughout the study.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M6J1H4
- Centre for Addiction and Mental Health
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Community-dwelling men and women aged 60 or above.
- Current cognitive complaints per participant self-report, but with intact cognitive function as defined by a score of 0-9 on the Short Blessed Test (SBT) and a Montreal Cognitive Assessment (MoCA) score ≥25 per PI discretion.
- PROMIS depression scale score of greater or equal to 16 and/or PROMIS anxiety score greater or equal to 14.
- Ability to read and speak English fluently enough to complete all research assessments.
- Corrected visual ability to read newspaper headlines.
- Hearing capacity to respond to a raised conversational voice.
- Willingness and ability to provide informed consent.
Exclusion Criteria:
- Diagnostic and Statistical Manual IV (DSM-IV) criteria for current or life-time bipolar disorder, schizophrenia, schizoaffective disorder or any other psychotic disorders.
- Untreated post-traumatic stress disorder.
- A MoCA score <25 or a score greater than 9 on the SBT, per PI discretion
- Use of cognitive enhancers such as anticholinergic medications within the past 6weeks.
- DSM-IV criteria for any substance dependence within the past 6 months that would affect their participation, per PI discretion.
- Unstable medical illness (e.g. uncontrolled diabetes mellitus or hypertension).
- Concurrent cognitive training, such as brain-training software, participation in psychotherapy or regular engagement in mindfulness practice and/or yoga.
- Taking anticonvulsant or antipsychotics that cannot be safely tapered and discontinued.
- Significant neurological condition (e.g. stroke, seizure disorder, multiple sclerosis).
- A pace-maker or other metal implants that would preclude safe use of tDCS.
- Intelligence Quotient (IQ) < 70 as estimated by the Wechsler Test of Adult Reading.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: TRIPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Active tDCS + MBSR
Excitatory bilateral stimulation to the frontal lobes, in particular the left and right DLPFC, will be applied. The anode will be placed at Fz and the cathode at Iz to achieve this bilateral frontal excitatory stimulation. Rubber electrodes will be inserted in 35-cm2 saline-soaked sponges and fixed with a headband. The direct current will be of 2 milliamps (mA) (current density = 0.57 A/m2) for 30 min per day. After a brief orientation session, the MBSR sessions will be conducted in 8 weekly 2.5 hour classes plus a half-day retreat. Content includes instruction and guidance to mindfulness meditation practices, gentle mindful movement, and various exercises to enhance mindfulness in everyday life. Participants will get daily at-home assignments with Compact Discs-Read Only Memory (CD-ROMs) of meditative practice. |
Excitatory bilateral stimulation to the frontal lobes, in particular the left and right DLPFC, will be applied.
The anode will be placed at Fz and the cathode at Iz to achieve this bilateral frontal excitatory stimulation.
Rubber electrodes will be inserted in 35-cm2 saline-soaked sponges and fixed with a headband.
The direct current will be of 2 mA (current density = 0.57 A/m2) for 30 min per day.
Other Names:
After a brief orientation session, the MBSR sessions will be conducted in 8 weekly 2.5 hour classes plus a half-day retreat.
Content includes instruction and guidance to mindfulness meditation practices, gentle mindful movement, and various exercises to enhance mindfulness in everyday life.
Participants will get daily at-home assignments with CDs of meditative practice.
Other Names:
|
SHAM_COMPARATOR: sham tDCS + MBSR
The same tDCS parameters as as the active condition will be used; however, the device will be turned off after 1 minute of active stimulation. After a brief orientation session, the MBSR sessions will be conducted in 8 weekly 2.5 hour classes plus a half-day retreat. Content includes instruction and guidance to mindfulness meditation practices, gentle mindful movement, and various exercises to enhance mindfulness in everyday life. Participants will get daily at-home assignments with CDs of meditative practice. |
After a brief orientation session, the MBSR sessions will be conducted in 8 weekly 2.5 hour classes plus a half-day retreat.
Content includes instruction and guidance to mindfulness meditation practices, gentle mindful movement, and various exercises to enhance mindfulness in everyday life.
Participants will get daily at-home assignments with CDs of meditative practice.
Other Names:
The same tDCS parameters as as the active condition will be used; however, the device will be turned off after 1 minute of active stimulation.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in cognitive and memory function
Time Frame: Baseline, Approximately 10-14 weeks after baseline
|
Cognitive and memory function measured by a neuropsychological battery examining memory, executive functioning and attention
|
Baseline, Approximately 10-14 weeks after baseline
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in depressive symptoms
Time Frame: Baseline, Approximately 10-14 weeks after baseline
|
Depressive symptoms as assessed by Patient-Reported Outcomes Measurement Information System (PROMIS) depressive symptoms
|
Baseline, Approximately 10-14 weeks after baseline
|
Change in anxiety symptoms
Time Frame: Baseline, Approximately 10-14 weeks after baseline
|
Anxiety symptoms as as assessed by Patient-Reported Outcomes Measurement Information System (PROMIS) anxiety symptoms
|
Baseline, Approximately 10-14 weeks after baseline
|
Change in quality of life
Time Frame: Baseline, Approximately 10-14 weeks after baseline
|
Quality of Life as assessed by PROMIS Scale for Ability to Participate in Social Roles and Activities, the PROMIS Scale for Satisfaction with Social Roles and Activities and the
|
Baseline, Approximately 10-14 weeks after baseline
|
Change in mindfulness
Time Frame: Baseline, Approximately 10-14 weeks after baseline
|
Mindfulness as assessed by Cognitive Affective Mindfulness Scale - Revised (CAMS-R)
|
Baseline, Approximately 10-14 weeks after baseline
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Tarek Rajji, Centre for Addiction and Mental Health
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 065/2017
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Mood Disorders
-
Université du Québec a MontréalCiusss de L'Est de l'Île de Montréal; PhysioExtra; EnergirRecruitingDepression ; Anxiety With Depressed Mood ; Mood Disorder, Adjustment Disorder With Depressed MoodCanada
-
Joliet Center for Clinical ResearchAbbottCompleted
-
National Institute of Mental Health (NIMH)Completed
-
National Institute of Mental Health (NIMH)Completed
-
University of North Carolina, Chapel HillNational Institute of Mental Health (NIMH)Completed
-
University of Colorado, DenverCompletedMood Disorders | Irritable MoodUnited States
-
VA Office of Research and DevelopmentCompleted
-
Baskent UniversityZİYAFET UĞURLURecruitingDisaster; Personality | Disorder, MoodTurkey
-
Fayoum University HospitalCompletedKetamine-Induced Mood DisorderEgypt
-
Mayo ClinicCompletedMood Disorders in Children and AdolescentsUnited States
Clinical Trials on Active tDCS
-
Bambino Gesù Hospital and Research InstituteCompleted
-
The University of Texas at DallasActive, not recruiting
-
University of California, Los AngelesNational Institute of Mental Health (NIMH)Completed
-
The University of Texas at DallasCompleted
-
Gaziler Physical Medicine and Rehabilitation Education...Active, not recruitingChronic StrokeTurkey
-
University of LiegeCompletedDisorders of ConsciousnessBelgium
-
University of Sao Paulo General HospitalFundação Faculdade de MedicinaCompleted
-
Ankara City Hospital BilkentActive, not recruitingChronic Spinal Cord DisorderTurkey
-
Spaulding Rehabilitation HospitalCompletedPelvic Pain | Pancreatitis | Visceral PainUnited States
-
The University of Texas Health Science Center,...Milken InstituteRecruiting